Shilpa Medicare receives EIR for Raichur facility

12 Apr 2017 Evaluate

Shilpa Medicare has received Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing facilities located at Raichur, Karnataka, which was inspected between December 12-16, 2016.

The inspection has now been closed by the USFDA. The company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection. The USFDA has reviewed the CAPA and has found them acceptable.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

300.20 13.00 (4.53%)
03-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1702.80
Dr. Reddys Lab 1235.00
Cipla 1322.45
Zydus Lifesciences 902.95
Lupin 2186.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×